Latest Information Update: 23 Aug 2002
At a glance
- Originator Unknown
- Developer Nonindustrial source
- Mechanism of Action Granulocyte colony stimulating factor stimulants; Immunomodulators; Interleukin stimulants; Tumour necrosis factor stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Cancer